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Edited by Miguel De la RosaAbstract The neural cell adhesion molecule (NCAM) can bind
to and activate ﬁbroblast growth factor receptor 1 (FGFR1).
However, there are four major FGFR isoforms (FGFR1–
FGFR4), and it is not known whether NCAM also interacts di-
rectly with the other three FGFR isoforms. In this study, we
show by surface plasmon resonance analysis that NCAM can
bind to FGFR2 with an aﬃnity similar to that for the
NCAM–FGFR1 interaction. However, the kinetic parameters
for the NCAM–FGFR2 binding are diﬀerent from those of the
NCAM–FGFR1 binding. Both receptors were shown to cycle
relatively fast between the NCAM bound and unbound states,
although FGFR2 cycling was clearly faster (13 times) than the
FGFR1 cycling. Moreover, ATP was more eﬀective in inhibiting
the binding of NCAM to FGFR1 than to FGFR2, indicating that
the binding sites in NCAM for the two receptors are similar, but
not identical.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ﬁbroblast growth factor receptors (FGFR1–FGFR4)
are a family of transmembrane tyrosine kinases involved in sig-
nalling via interactions with the family of ﬁbroblast growth
factors (FGF1–FGF23) [5]. FGFRs regulate a multitude of
cellular processes including cell growth, diﬀerentiation, migra-
tion and survival, and have been implicated in a number of
physiological and pathological processes including angiogene-
sis, wound healing and cancer. The prototypical FGFR con-
sists of three immunoglobulin (Ig) modules (Ig1–Ig3), a
transmembrane helix and a cytoplasmic tyrosine kinase do-
main. FGF-FGFR binding results in the FGFR dimerization
leading to auto-phosphorylation of the receptor tyrosine ki-
nase domains [10]. The FGFR–ligand interaction is mediated
by the Ig2 and Ig3 modules, while the Ig1 module is thought
to have a regulatory function.
FGFR1 can also be activated by cell adhesion molecules
such as L1, N-cadherin and the neural cell adhesion molecule
(NCAM). NCAM belongs to the Ig superfamily and consists*Corresponding author. Fax: +45 35 36 01 16.
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doi:10.1016/j.febslet.2006.05.008of ﬁve extracellular Ig modules, two ﬁbronectin type III (F3)
modules and a cytoplasmic part of varying length [1]. NCAM
mediates cell–cell and cell–substratum adhesion by means of
homophilic binding and numerous heterophilic interactions
[11]. The homophilic interaction mediated by NCAM leads
to activation of FGFR1, which in turn results in a context-
dependent biological response, such as induction of axonal
growth during development, as well as modulation of synap-
tic plasticity. The structural determinants for the NCAM–
FGFR1 interaction have recently been characterized [6,7]. It
was shown by surface plasmon resonance (SPR) analysis that
an NCAM fragment consisting of the ﬁrst and second F3
modules bound to the Ig2–Ig3 modules of the FGFR1 (3C
subtype) with a dissociation constant (Kd) of 10 lM. The
NCAM–FGFR1 interaction site in NCAM was further
mapped by nuclear magnetic resonance (NMR) analysis to
the FG loop region of the second F3 module, and a peptide
corresponding to this region (termed FGL) was capable of
binding to the FGFR1 Ig modules 2 and 3 [6]. The FGL pep-
tide also has been shown to induce neurite outgrowth in pri-
mary neurons and promote neuronal cell survival in vitro and
in vivo [8,9] The FG loop region of the second F3 module of
NCAM contains an ATP binding motif and is thought to be
responsible for the ATPase activity of NCAM. The function
of the ATPase activity of NCAM is not fully understood.
However, it was shown by NMR that the second F3 module
of NCAM binds ATP via its ATP binding motif, and by SPR
it was shown that ATP can inhibit the NCAM–FGFR1 inter-
action, thus suggesting that ATP may be a regulator of the
NCAM–FGFR1 interaction. This notion is further supported
by the fact that ATP inhibits NCAM-mediated neurite out-
growth [6]. Since there are four major FGFR isoforms, it is
of interest to test if NCAM also can bind to the other iso-
forms, FGFR2 in particular. A number of identiﬁed missense
mutations in FGFR2 has been shown to lead to craniofacial
pathology due to premature fusion of cranial sutures, a hall-
mark of over 100 distinct syndromes, including Apert, Pfeiﬀer
and Crouzon syndromes [3].
Here we show by SPR that the combined ﬁrst and second F3
modules of NCAM and the FGL peptide bind to the combined
second and third Ig modules of FGFR2 (3C subtype) with Kd
values of 9.21 and 1.75 lM, respectively, and that ATP is able
to inhibit these interactions. Thus, the aﬃnity of the NCAM–
FGFR2 interaction appears to be similar to that of the
NCAM–FGFR1 interaction. Based on this, we propose that
NCAM can activate FGFR2. However, although both recep-
tors were shown to cycle relatively fast between the NCAM
bound and unbound state, FGFR2 cycling was clearly fasterblished by Elsevier B.V. All rights reserved.
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Fig. 1. Binding of FGF1 to the FGFR1 and FGFR2 Ig modules 2–3.
FGF1 concentration was 100 nM.2. Results
In order to study the NCAM–FGFR2 interaction, we used
recombinant proteins consisting of the NCAM F3 modules
1–2 [6], and the FGFR2 (3C subtype) Ig modules 2–3. Both re-
combinant proteins were expressed in a yeast expression sys-
tem of Pichia pastoris. To test if the FGFR2 fragment was
expressed in a functionally active form, the protein was immo-
bilized on the surface of a CM-5 sensor chip, and its binding to
FGF1 was studied by SPR and compared to that of the corre-
sponding FGFR1 fragment, which previously had been ex-
pressed in Drosophila cells and by NMR analysis was shown
to be properly folded [6]. The binding curves for the
FGFR1-FGF1 and FGFR2-FGF1 interactions are shown in
Fig. 1. The Kd values for both interactions were estimated to
be approximately 5 nM, which is similar to the Kd values for
this interaction obtained by other researchers using SPR [4].
Thus, the immobilized FGFR2 fragment appears to be func-
tional and suitable for further analysis.
2.1. The NCAM F3 modules 1–2 and the FGL peptide bind to
the FGFR2 Ig modules 2–3
Since it previously had been shown that the NCAM F3 mod-
ules 1–2 bound to the FGFR1 Ig modules 2–3 [6], it was of0 50 100 150 200
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Fig. 2. Binding of the NCAM F3 modules 1–2 and the FGL peptide to the F
binding of the FGL peptide at the speciﬁed concentrations. (B) The equi
concentration and the ﬁtted curve.interest to test if this interaction was similar to that of NCAM
and FGFR2. Therefore, binding of the immobilized FGFR2 Ig
modules 2–3 to soluble NCAM F3 modules 1–2 was studied by
SPR (Fig. 2A). In order to determine the Kd value of the
NCAM–FGFR2 interaction, the equilibrium binding level of
the F3 modules was plotted versus the concentration of the
F3 modules in solution and ﬁtted with an equation describing
the single-site receptor–ligand equilibrium binding (Fig. 2B).150 200 250
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Kd = 9.21 ± 3.14 µM
GFR2 Ig modules 2–3. (A) Binding of the NCAM fragment, and (C)
librium binding level of the NCAM fragment versus the fragment’s
3388 C. Christensen et al. / FEBS Letters 580 (2006) 3386–3390The equilibrium binding analysis method was chosen instead
of ﬁtting the individual association and dissociation phases be-
cause the association phase (Fig. 2A) was atypical. The coeﬃ-
cient of dissociation rate (kd) was determined by ﬁtting the
dissociation phase with the corresponding equation, and the
coeﬃcient of association rate (ka) was estimated by dividing
kd with Kd. In comparison to the NCAM–FGFR1 binding,
the NCAM–FGFR2 binding is characterized by much faster
association and dissociation phases and approximately the
same aﬃnity. A detailed comparison of the kinetic parameters
for the two interactions is shown in Table 1. We also tested
binding of the FGFR2 fragment to the FGL peptide
(Fig. 2C), previously shown to bind FGFR1 [6]. The FGL pep-
tide corresponds to a binding site for FGFR1 in NCAM (the
FG loop region of the NCAM F3 module 2). The calculated
Kd value for the FGFR2-FGL interaction was very similar
to that for the FGFR1-FGL interaction (see Table 1).
Thus, it appears from these experiments, that NCAM can
bind FGFR2, and that the NCAM sites for FGFR1 and
FGFR2 may be similar.
2.2. Analysis of the eﬀect of ATP on the NCAM–FGFR2
interaction
Previously it has been shown that the NCAM–FGFR1 inter-
action can be inhibited by ATP [6]. ATP was shown to inhibit
the NCAM–FGFR1 interaction by means of a competitiveTable 1
Summary of the kinetic parameters for the interaction between Ig module 2
peptide
ka (M
1 s1) kd (s
1)
FGFR2/FGF1 3.85 ± 1.11 · 105 1.44 ± 0.14 · 102
FGFR1/FGF1 3.14 ± 0.62 · 105 1.65 ± 0.10 · 102
FGFR2/NCAM 8.10 ± 2.81 · 103 7.42 ± 0.10 · 102
FGFR1/NCAMa 8.89 ± 3.32 · 102 5.33 ± 0.07 · 103
FGFR2/FGL 5.31 ± 2.43 · 103 1.01 ± 0.01 · 102
FGFR1/FGLa
aData from Kiselyov et al. [6].
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Fig. 3. Demonstration of an inhibition by ATP of the binding between the
peptide. (A) Binding of the 35 lM NCAM fragment, and (B) binding o
concentrations.inhibition mechanism, namely: ATP bound to the ATP bind-
ing motif located in the FG loop region of the F3 module 2
of NCAM, and this region of NCAM was also shown to be
a binding site for FGFR1 [6]. Since the NCAM sites for
FGFR1 and FGFR2 appear to be similar, the NCAM–
FGFR2 interaction could also be expected to be inhibited by
ATP. To test this assumption, binding of the F3 modules 1–
2 of NCAM and the FGL peptide to the FGFR2 Ig modules
2–3 in the presence of the various concentrations of ATP
was studied by SPR. As appears from Fig. 3A and B, ATP
inhibited binding to the FGFR2 fragment of both the F3 mod-
ules 1–2 of NCAM and the FGL peptide. In order to compare
the eﬀect of ATP on the NCAM–FGFR2 interaction with that
of the NCAM–FGFR1 interaction, the inhibition constant
(Ki) should be calculated. However, due to the fact that the
highest concentration of ATP (5 mM) did not inhibit the bind-
ing completely, and because it was not possible to measure pre-
cisely the initial binding rate due to very fast association, it was
not possible to calculate the Ki value employing the same
methodology as the one used for the NCAM–FGFR1 interac-
tion. As a rough estimate of the Ki value, the ATP concentra-
tion that inhibited binding by 50% (IC50) was therefore
determined. The IC50 value for the NCAM–FGFR2 interac-
tion was estimated as approximately 5.2 mM (see Table 1),
which is 14-fold higher than the 0.37 mM Ki value found for
the NCAM–FGFR1 interaction. Thus, it appears from these–3 of FGFR1/FGFR2 and FGF1 or NCAM F3 modules 1–2 or FGL
Kd (M) Ki/IC50 (M)
4.91 ± 1.56 · 108
5.60 ± 0.93 · 108
9.21 ± 3.14 · 106 5.22 ± 2.09 · 103 (IC50)
9.97 ± 0.37 · 106 3.70 ± 0.01 · 104 (Ki)
1.75 ± 1.39 · 106 8.00 ± 3.79 · 103 (IC50)
2.58 ± 2.06 · 106
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tion. However, ATP seems to be 14 times less eﬀective in inhib-
iting the NCAM–FGFR2 binding in comparison to the
NCAM–FGFR1 binding.3. Discussion
In this study we have shown that the NCAM F3 modules 1–
2 bound to the FGFR2 Ig modules 2–3 with a Kd value of
9.21 lM, which is very similar to the 10 lM Kd value for the
NCAM–FGFR1 interaction. Since the NCAM concentration
in the membrane of neurons was estimated to be on average
50 lM, then according to previous calculations [6], around
85% of the FGFR2 molecules are expected to be bound by
NCAM under physiological conditions. For the NCAM–
FGFR1 interaction, approximately 83% of the FGFR1 mole-
cules are expected to be bound by NCAM under the same
conditions. Based on the fact that the NCAM–FGFR1 inter-
action can lead to activation of FGFR1, and the fact that
the calculated percentages of FGFR1 and FGFR2 molecules
expected to be bound by NCAM are similar, we propose that
NCAM also can activate FGFR2.
Both the NCAM–FGFR1 and NCAM–FGFR2 interactions
are characterized by relatively fast association and dissociation
phases. From the kinetic parameters of these interactions (see
Table 1), we can estimate that the stability of the NCAM–
FGFR1 complex is approximately 200 s, and that of the
NCAM–FGFR2 – approximately 15 s. Thus, FGFR1 and
FGFR2 cycle between the NCAM bound and unbound forms
relatively quickly, but the FGFR2 cycling is approximately 13
times faster than that of FGFR1. The possible physiological
signiﬁcance of the faster cycling by FGFR2 is not immediately
apparent, because compared to the time scale of a physiologi-
cal response such as neurite-induction, which requires many
hours (possibly days), the stability of both complexes is negli-
gible. However, NCAM may be expected to be less eﬀective in
activating FGFR2 than FGFR1, if the time-period required
for activation of FGFR is longer than the stability of the
NCAM–FGFR2 complex. Whether or not this is true requires
further investigation.
The FGL peptide bound to FGFR2 with an aﬃnity similar
to that of the FGL–FGFR1 interaction. This indicates that the
NCAM sites binding to FGFR2 and FGFR1 are similar,
namely: the FG loop region of the NCAM F3 module 2. This
is further supported by the fact that ATP, which binds the
ATP binding motif located in the NCAM F3 module 2, inhib-
ited the NCAM–FGFR2 interaction. However, ATP was
found to be 14 times less eﬀective in inhibiting the NCAM–
FGFR2 interaction compared to the NCAM–FGFR1 interac-
tion, indicating that although the NCAM sites binding to
FGFR1 and FGFR2 are similar, they are not identical. Taking
into consideration that the highest local concentration of ATP
in synaptic vesicles is approximately 1 mM, if in free solution
[2], and the fact that ATP inhibits the NCAM–FGFR2 bind-
ing with an IC50 value of approximately 5 mM, ATP is not ex-
pected to signiﬁcantly aﬀect the NCAM–FGFR2 binding
under physiological conditions, and thus play a role in regula-
tion of the NCAM–FGFR2 interaction. However, a regula-
tory role of ATP cannot be entirely excluded.
Thus, in this study we demonstrated that the structural
parameters and aﬃnity of the NCAM–FGFR2 binding aresimilar to that of the NCAM–FGFR1 binding, which allows
us to presume that NCAM can activate FGFR2 in the same
way as it activates FGFR1.4. Methods
4.1. Production of recombinant proteins
The combined Ig2–3 modules of rat FGFR2 consist of a His-tag,
AGHHHHHHE, and amino acids 166–384 (swissprot Q63237). The
FGFR2 construct was expressed in the KM71 strain of yeast P. pasto-
ris (Invitrogen, USA) according to the manufacturer’s instructions.
The NCAM F3 modules 1–2 were produced in P. pastoris as previously
described [6]. The FGFR2 and NCAM constructs were puriﬁed by
aﬃnity chromatography using Ni2+-NTA resin (Qiagen, USA) and/
or ion exchange chromatography and gel ﬁltration. The rat full-length
FGF1 (amino acids 1–155, swissprot P61149) was expressed in a
TOP10F 0 strain of Escherichia coli (Invitrogen) and puriﬁed by aﬃnity
chromatography using heparin resin.
4.2. SPR analysis
Binding analysis was performed using a BIAcoreX instrument (Bio-
sensor AB, Sweden) at 25 C using 10 mM sodium phosphate, pH 7.4,
150 mM NaCl as running buﬀer. The ﬂow-rate was 5 ll/min. The Ig2–
3 modules of FGFR1 or FGFR2 were immobilized on the sensor chip
CM5 (Biosensor AB, Sweden) as previously described [6]. Approx.
2000 resonance units (RU) of the FGFR modules were immobilized
on the sensor chip. Binding was studied in the following way: A com-
pound was injected at a speciﬁed concentration simultaneously into a
ﬂow-cell with the immobilized FGFR modules (Fc1-cell) and a control
ﬂow-cell with nothing immobilized (Fc2-cell). The curve representing
unspeciﬁc binding of the compound to the surface of the Fc2-cell
was subtracted from the curve representing binding of the same
compound to the immobilized Ig2–3 modules and the surface of the
Fc1-cell. The resulting curve was used for analysis. The kinetic con-
stants were calculated from the dissociation and association phases
using the manufacture’s software. Three independent experiments were
performed.
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